The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world.

Following a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), the European Commission on Monday 19th December formally approved Atara Biotherapeutics’ Ebvallo (tabelecleucel) for the treatment of Epstein-Barr virus-positive, post-transplant lymphoproliferative disease in patients who have undergone at least one prior therapy.

Read the full article to learn more about what this watershed moment means not just for the CGT industry, but for cryogenic logistics too.